1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Neurimmune Therapeutics AG - Product Pipeline Review - 2013

Neurimmune Therapeutics AG - Product Pipeline Review - 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 16 pages

Neurimmune Therapeutics AG - Product Pipeline Review - 2013


Summary


Global Market Direct’s pharmaceuticals report, “Neurimmune Therapeutics AG - Product Pipeline Review - 2013” provides data on the Neurimmune Therapeutics AG’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Neurimmune Therapeutics AG’s corporate website, SEC filings, investor presentations and featured press releases, both from Neurimmune Therapeutics AG and industry-specific third party sources, put together by Global Markets Direct’s team.


Scope


- Neurimmune Therapeutics AG - Brief Neurimmune Therapeutics AG overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Neurimmune Therapeutics AG human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Neurimmune Therapeutics AG with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Neurimmune Therapeutics AG’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.


Reasons to buy


- Evaluate Neurimmune Therapeutics AG’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Neurimmune Therapeutics AG in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Neurimmune Therapeutics AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Neurimmune Therapeutics AG.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Neurimmune Therapeutics AG and identify potential opportunities in those areas.

Table Of Contents

Neurimmune Therapeutics AG - Product Pipeline Review - 2013
Table of Contents 2
List of Tables 3
List of Figures 3
Neurimmune Therapeutics AG Snapshot 4
Neurimmune Therapeutics AG Overview 4
Key Information 4
Key Facts 4
Neurimmune Therapeutics AG - Research and Development Overview 5
Key Therapeutic Areas 5
Neurimmune Therapeutics AG - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Out-Licensed Products/Combination Treatment Modalities 9
Neurimmune Therapeutics AG - Pipeline Products Glance 10
Neurimmune Therapeutics AG - Early Stage Pipeline Products 10
Pre-Clinical Products/Combination Treatment Modalities 10
Neurimmune Therapeutics AG - Drug Profiles 11
NI-203 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
Neurimmune Therapeutics AG - Pipeline Analysis 12
Neurimmune Therapeutics AG - Pipeline Products by Therapeutic Class 12
Neurimmune Therapeutics AG - Dormant Projects 13
Neurimmune Therapeutics AG - Locations And Subsidiaries 14
Head Office 14
Appendix 15
Methodology 15
Coverage 15
Secondary Research 15
Primary Research 15
Expert Panel Validation 15
Contact Us 16
Disclaimer 16

List of Tables


Neurimmune Therapeutics AG, Key Information 4
Neurimmune Therapeutics AG, Key Facts 4
Neurimmune Therapeutics AG - Pipeline by Indication, 2013 6
Neurimmune Therapeutics AG - Pipeline by Stage of Development, 2013 7
Neurimmune Therapeutics AG - Monotherapy Products in Pipeline, 2013 8
Neurimmune Therapeutics AG - Out-Licensed Products/ Combination Treatment Modalities, 2013 9
Neurimmune Therapeutics AG - Pre-Clinical, 2013 10
Neurimmune Therapeutics AG - Pipeline By Therapeutic Class, 2013 12
Neurimmune Therapeutics AG - Dormant Developmental Projects,2013 13

List of Figures


Neurimmune Therapeutics AG - Pipeline by Indication, 2013 6
Neurimmune Therapeutics AG - Pipeline by Stage of Development, 2013 7
Neurimmune Therapeutics AG - Monotherapy Products in Pipeline, 2013 8
Neurimmune Therapeutics AG - Pipeline By Therapeutic Class, 2013 12

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.